Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 20 de 30
Filter
1.
Med J Malaysia ; 78(3): 421-426, 2023 05.
Article in English | MEDLINE | ID: covidwho-20235551

ABSTRACT

OBJECTIVES: Severe, acute, respiratory syndromecoronavirus- 2 (SARS-CoV-2) infections can be complicated by central nervous system (CNS) disease. One of the CNS disorders associated with Coronavirus Disease-19 (COVID- 19) is posterior reversible encephalopathy syndrome (PRES). This narrative review summarises and discusses previous and recent findings on SARS-CoV-2 associated PRES. METHODS: A literature search was carried out in PubMed and Google Scholar using suitable search terms and reference lists of articles found were searched for further articles. RESULTS: By the end of February 2023, 82 patients with SARS-CoV-2 associated PRES were recorded. The latency between the onset of COVID-19 and the onset of PRES ranged from 1 day to 70 days. The most common presentations of PRES were mental deterioration (n=47), seizures (n=46) and visual disturbances (n=18). Elevated blood pressure was reported on admission or during hospitalisation in 48 patients. The most common comorbidities were arterial hypertension, diabetes, hyperlipidemia and atherosclerosis. PRES was best diagnosed by multimodal cerebral magnetic resonance imaging (MRI). Complete recovery was reported in 35 patients and partial recovery in 21 patients, while seven patients died. CONCLUSIONS: PRES can be a CNS complication associated with COVID-19. COVID-19 patients with mental dysfunction, seizures or visual disturbances should immediately undergo CNS imaging through multimodal MRI, electroencephalography (EEG) and cerebrospinal fluid (CSF) studies in order not to miss PRES.


Subject(s)
COVID-19 , Hypertension , Posterior Leukoencephalopathy Syndrome , Humans , Posterior Leukoencephalopathy Syndrome/diagnosis , Posterior Leukoencephalopathy Syndrome/etiology , SARS-CoV-2 , COVID-19/complications , Seizures/etiology , Electroencephalography/adverse effects , Electroencephalography/methods , Hypertension/complications , Magnetic Resonance Imaging/methods
2.
Revista Medica De Chile ; 150(8):1121-1121, 2022.
Article in English | Web of Science | ID: covidwho-2308451
4.
Eur Rev Med Pharmacol Sci ; 26(3): 734-735, 2022 02.
Article in English | MEDLINE | ID: covidwho-2230003
6.
Revista Medica de Chile ; 150(5):695-696, 2022.
Article in English | EMBASE | ID: covidwho-2163846
7.
Archivos Argentinos de Pediatria ; 120(6):e359-e360, 2022.
Article in Spanish, English | MEDLINE | ID: covidwho-2116781
8.
Journal of Neuromuscular Diseases ; 9:S160, 2022.
Article in English | EMBASE | ID: covidwho-2043383

ABSTRACT

Objectives: Guillain-Barre syndrome (GBS) is an established manifestation of neuro-COVID. Here we summarise and discusses recent findings concerning the pathophysiology, clinical presentation, diagnosis, treatment and outcome of SARS-CoV- 2-associated GBS (SC2-GBS). Methods: Literature review Results: By the end of December 2020, at least 220 patients with SC2-GBS have been published in 95 papers. SC2-GBS is most likely secondary due to an immune reaction against SARS-CoV-2 since the virus has not been found in the CSF of any SC2- GBS patient so far reported. SC2-GBS occurs in each age group, does not differ from non-SC2-GBS regarding clinical presentation and treatment but the outcome of SC2-GBS is worse compared to non- CS2-GBS patients, and the prevalence/incidence of GBS most likely increased since the outbreak of the pandemic. Conclusions: SC2-GBS is most likely secondary to an immune reaction against SARS-CoV-2 since the virus has not been found in CSF of any SC2- GBS patient reported. SC2-GBS occurs at any age. SC2-GBS does not differ from non-SC2-GBS regarding clinical presentation and treatment but the outcome of SC2-GBS is worse compared to non- CS2-GBS patients. The prevalence/incidence of GBS most likely increased since the outbreak of the pandemic. Since there are no studies about the optimal treatment of SC2-GBS subtypes available, they should be treated empirically in the same way as non-SC2-GBS subtypes. Early diagnosis of SC2- GBS is warranted because if appropriate treatment is applied in due time the overall outcome from the infection may improve.

9.
Med Intensiva (Engl Ed) ; 46(10): 594-595, 2022 10.
Article in English | MEDLINE | ID: covidwho-2042027
10.
Rev Neurol ; 74(12): 408, 2022 06 16.
Article in English, Spanish | MEDLINE | ID: covidwho-1893685

ABSTRACT

TITLE: La evolución del síndrome de Guillain-Barré asociado al SARS-CoV-2 depende del tratamiento temprano y de la vacunación.


Subject(s)
COVID-19 , Guillain-Barre Syndrome , Guillain-Barre Syndrome/etiology , Humans , SARS-CoV-2 , Vaccination
11.
Medicina del Lavoro ; 113(1), 2022.
Article in English | Scopus | ID: covidwho-1738134
13.
Med Intensiva ; 46(10): 594-595, 2022 Oct.
Article in English | MEDLINE | ID: covidwho-1611912
14.
Revue neurologique ; 2021.
Article in English | EuropePMC | ID: covidwho-1601964
15.
Israel Medical Association Journal: Imaj ; 23(9):603, 2021.
Article in English | MEDLINE | ID: covidwho-1391142
16.
J Neuroimmunol ; 357: 577626, 2021 08 15.
Article in English | MEDLINE | ID: covidwho-1313262
17.
J Med Ultrasound ; 29(2): 134-135, 2021.
Article in English | MEDLINE | ID: covidwho-1296045
18.
QJM ; 114(11): 835, 2022 01 05.
Article in English | MEDLINE | ID: covidwho-1288099
SELECTION OF CITATIONS
SEARCH DETAIL